Press Release

Epivir Tablets for Pediatric Dosing

From U.S. Food and Drug Administration

February 7, 2008

FDA has approved a new formulation of Epivir (lamivudine) designed to facilitate dosing in appropriate pediatric patients who can reliably swallow tablets. Epivir is now available as 150 mg scored tablets. The scored tablets allow for dosing recommendations in pediatric patients. The DOSING AND ADMINISTRATION section of the Epivir label was revised as follows:

Pediatric Patients

The recommended oral dose of EPIVIR Oral Solution in HIV-1-infected pediatric patients 3 months to 16 years of age is 4 mg/kg twice daily (up to a maximum of 150 mg twice a day), administered in combination with other antiretroviral agents.

EPIVIR is also available as a scored tablet for HIV-1-infected pediatric patients who weigh =14 kg for whom a solid dosage form is appropriate. Before prescribing EPIVIR Tablets, children should be assessed for the ability to swallow tablets. If a child is unable to reliably swallow EPIVIR Tablets, the oral solution formulation should be prescribed. The recommended oral dosage of EPIVIR Tablets for HIV-1-infected pediatric patients is presented in Table 1.

A pdf version of Table 1 is attached.

Epivir is a Nucleoside Reverse Transcriptase Inhibitor (NRTI) manufactured by GlaxoSmithKline.

FDA Says Merck's HIV Drug Gets Generic Threat

Two New Fixed-Dose Combinations Approved

This article was provided by U.S. Food and Drug Administration. Visit the FDA's website to find out more about their activities and publications.

More on HIV Medications

More News on 3TC (Lamivudine, Epivir)

10 Questions to Ask Yourself Before You Begin HIV Treatment

Getting to Undetectable: People Living With HIV Share Their Stories

HIV Management Today: Mental Health & HIV, the Uncharted Territory

Get TheBody.com in the Palm of Your Hand

Day One With HIV: "I Had Never Actually Met Anyone Who Was Positive"

More >>

New! TheBody.com App

My Health Tracker

Medication and Health Reminders

Assess Your Risk for HIV

U.S. ASO Finder

The Body is a service of Remedy Health Media, LLC, 500 5th Avenue, 19th Floor, New York, NY 10110. The Body and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.